111 related articles for article (PubMed ID: 38211602)
1. Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
Cossmann A; Hoffmann M; Stankov MV; Lürken K; Morillas Ramos G; Kempf A; Nehlmeier I; Pöhlmann S; Behrens GMN; Dopfer-Jablonka A
Lancet Infect Dis; 2024 Mar; 24(3):e145-e146. PubMed ID: 38211602
[No Abstract] [Full Text] [Related]
2. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
Stankov MV; Hoffmann M; Gutierrez Jauregui R; Cossmann A; Morillas Ramos G; Graalmann T; Winter EJ; Friedrichsen M; Ravens I; Ilievska T; Ristenpart J; Schimrock A; Willenzon S; Ahrenstorf G; Witte T; Förster R; Kempf A; Pöhlmann S; Hammerschmidt SI; Dopfer-Jablonka A; Behrens GMN
Lancet Infect Dis; 2024 Jan; 24(1):e1-e3. PubMed ID: 37995739
[No Abstract] [Full Text] [Related]
3. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
[TBL] [Abstract][Full Text] [Related]
4. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
Yau K; Kurtesi A; Qi F; Delgado-Brand M; Tursun TR; Hu Q; Dhruve M; Kandel C; Enilama O; Levin A; Jiang Y; Hardy WR; Yuen DA; Perl J; Chan CT; Leis JA; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
Nat Commun; 2023 Sep; 14(1):6041. PubMed ID: 37758707
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.
Puspitasari M; Sattwika PD; Hidayat ARP; Wijaya W; Wardhani Y; Intansari US; Kertia N; Purwanto B; Thobari JA
BMC Nephrol; 2023 May; 24(1):151. PubMed ID: 37248445
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
Lancet Infect Dis; 2024 Feb; 24(2):e80-e81. PubMed ID: 38190833
[No Abstract] [Full Text] [Related]
7. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
8. Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2.
Thieme CJ; Blazquez-Navarro A; Safi L; Kaliszczyk S; Paniskaki K; Neumann IE; Schmidt K; Stockhausen M; Hörstrup J; Cinkilic O; Flitsch-Kiefner L; Meister TL; Marheinecke C; Pfaender S; Steinmann E; Seibert FS; Stervbo U; Westhoff TH; Roch T; Babel N
J Am Soc Nephrol; 2021 Nov; 32(11):2725-2727. PubMed ID: 34716240
[No Abstract] [Full Text] [Related]
9. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
[TBL] [Abstract][Full Text] [Related]
10. Is the BNT162b2 vaccine still effective against the latest variant: XBB.1.5?
Erdag E; Sultanoglu N; Ozverel CS
Niger J Clin Pract; 2023 Oct; 26(10):1519-1524. PubMed ID: 37929529
[TBL] [Abstract][Full Text] [Related]
11. Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2.
Patecki M; Merscher S; Dumann H; Bernhardt W; Dopfer-Jablonka A; Cossmann A; Stankov MV; Einecke G; Haller H; Schlieper G; Behrens GM
Perit Dial Int; 2022 Jan; 42(1):100-101. PubMed ID: 34753339
[No Abstract] [Full Text] [Related]
12. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.
El Karoui K; De Vriese AS
Kidney Int; 2022 May; 101(5):883-894. PubMed ID: 35176326
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
14. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.
Kanai D; Wakui H; Hanaoka M; Haze T; Azushima K; Shinoda S; Tsukamoto S; Taguchi S; Kinguchi S; Kanaoka T; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2023 Jul; 27(7):639-647. PubMed ID: 36977892
[TBL] [Abstract][Full Text] [Related]
15. Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination.
Dulovic A; Strengert M; Ramos GM; Becker M; Griesbaum J; Junker D; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
Emerg Infect Dis; 2022 Apr; 28(4):743-750. PubMed ID: 35203113
[TBL] [Abstract][Full Text] [Related]
16. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
Front Immunol; 2022; 13():840136. PubMed ID: 35309320
[TBL] [Abstract][Full Text] [Related]
18. Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients.
Haarhaus M; Duhanes M; Leševic N; Matei B; Ramsauer B; Da Silva Rodrigues R; Su J; Haase M; Santos-Araújo C; Macario F
Scand J Immunol; 2022 May; 95(5):e13152. PubMed ID: 35244289
[TBL] [Abstract][Full Text] [Related]
19. Diminished T-cell immune responses to SARS-CoV-2 omicron variant after BNT162b2 vaccination.
Jordan SC; Shin BH; Rodriguez E; Vo A; NorikoAmmerman ; Zhang R
Immunol Lett; 2022 Aug; 248():123-125. PubMed ID: 35843362
[No Abstract] [Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
